Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

Table 1 The A₅₇₀ values of different treatments on DEHs when adding virus firstly (n = 6)

GP Concentration (μg^.mL^− 1)	A ₅₇₀	Hepatocyte protection rate (%)	pGP Concentration (μg^.mL^− 1)	A ₅₇₀	Hepatocyte protection rate (%)
100	0.338 ± 0.009^b	51.91	25	0.523 ± 0.008^a	113.42
50	0.229 ± 0.007^c	19.94	12.5	0.486 ± 0.007^b	97.40
25	0.167 ± 0.010^d	1.76	6.25	0.458 ± 0.007^c	85.28
12.5	0.174 ± 0.006^d	3.81	3.125	0.380 ± 0.006^d	51.52
0(VC)	0.161 ± 0.006^d		0(VC)	0.261 ± 0.009^e
0(CC)	0.502 ± 0.003^a		0(CC)	0.492 ± 0.008^a

^a-eData in same column without same superscript (a–e) differ significantly(p < 0.05)
GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control

ISSN: 1746-6148